Ferozsons Laboratories announced Financial Results for the period ended June 30, 2017.
The company’s Net Revenue for the period decreased by 57.67 percent in the outgoing year, whereas the Profit after Taxation for the Period decreased by 81 percent.
The board did not recommend any interim Cash Dividend, no bonus or right shares.
Comparison of Key Financials
Unconsolidated Profit and Loss Account – For the Twelve Months Ended
Key Financials
2017
2016
% Change
Amounts in PKR
Net Revenue
4,311,441,718
10,186,496,154
-57.67%
Cost of Sales
2,534,669,504
6,077,657,868
-58.30%
Gross Profit
1,776,772,214
4,108,838,286
-56.76%
Admin: Expenses
289,129,914
276,235,535
4.67%
Selling & Dist: Expenses
913,763,385
1,033,035,251
-11.55%
Other Expenses
3,216,963
260,905,050
-98.77%
Other income
47,849,556
126,515,313
-62.18%
Profit from Operations
618,511,508
2,665,177,763
-76.79%
Finance Costs
16,293,573
11,152,570
46.10%
Profit before Taxation
602,217,935
2,654,025,193
-77.31%
Taxation
208,553,225
549,538,096
-62.05%
Profit after Taxation
393,664,710
2,104,487,097
-81.29%
EPS – Basic & diluted
13.04
69.72
-81.30%
Company release on Earnings Report can be accessed here.